BNP Paribas Asset Management
ORIC icon

BNP Paribas Asset Management’s Oric Pharmaceuticals ORIC Stock Holding History

BNP Paribas Asset Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.1K Buy
1,114
+467
+72% +$5.3K ﹤0.01% 2128
2025
Q4 		$5K Buy
647
+99
+18% +$1.14K ﹤0.01% 2262
2025
Q3 		$7K Buy
+548
New +$5.76K ﹤0.01% 1744

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BNP Paribas Asset Management's ORIC Position: Q1 2026 in Review

BNP Paribas Asset Management increased its Oric Pharmaceuticals (ORIC) stake by 72% in Q1 2026, buying an estimated $5.3K and bringing the position to 1,114 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2128.

BNP Paribas Asset Management first reported a position in ORIC in Q3 2025 and has held it in 3 quarters since. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • BNP Paribas Asset Management held 1,114 shares of Oric Pharmaceuticals worth $14.1K as of Q1 2026.
  • BNP Paribas Asset Management bought 467 Oric Pharmaceuticals shares in Q1 2026, an estimated $5.3K.
  • Oric Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #2128 holding.
  • BNP Paribas Asset Management first reported a position in Oric Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.